Holen Sie sich die Stockscreener-App
79.78
1.09%
0.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$78.92
Offen:
$78.6
24-Stunden-Volumen:
4.74M
Relative Volume:
1.23
Marktkapitalisierung:
$46.30B
Einnahmen:
$6.07B
Nettoeinkommen (Verlust:
$1.06B
KGV:
43.06
EPS:
1.8527
Netto-Cashflow:
$799.60M
1W Leistung:
+5.15%
1M Leistung:
-4.41%
6M Leistung:
-1.98%
1J Leistung:
+6.79%
1-Tages-Spanne:
$78.00
$79.93
1-Wochen-Bereich:
$76.33
$80.42
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences Stock at $78: Here’s the Analysts’ Bull Case Scenario - TIKR.com
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing - The Motley Fool
Edwards Lifesciences CFO set for back-to-back global healthcare talks - Stock Titan
First National Bank of Omaha Purchases New Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Alberta Investment Management Corp Buys Shares of 68,300 Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences advances smart surgery monitoring with completed SMART TRENDS study - MSN
Edwards Lifesciences Corporation $EW Holdings Raised by Vanguard Group Inc. - MarketBeat
Edwards Lifesciences (NYSE:EW) Trading Up 5.6%Here's Why - MarketBeat
Edwards Lifesciences Corp. Drops ‘Anti-Copycatting’ Policy Amid EU Probe - USA Herald
Edwards Sued In Chancery Over $300M Heart Valve Earn-Out - Law360
Edwards Lifesciences (EW) Rises as EU Antitrust Probe Ends - GuruFocus
Edwards Lifesciences (EW) Experiences Significant Price Surge - GuruFocus
European Commission ends Edwards antitrust probe after company withdraws anti-copycat policy - MassDevice
Edwards Lifesciences Corporation $EW Shares Sold by PNC Financial Services Group Inc. - MarketBeat
Edwards Lifesciences (NYSE:EW) Shows Institutional Concentration Trends Within The S&P 500 Today - Kalkine Media
Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88% - Yahoo Finance
Tobam Has $5.22 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
EU Closes Antitrust Investigation Against US' Edwards Lifesciences - marketscreener.com
Edwards Lifesciences scraps anti-copycat policy, EU drops antitrust investigation - Reuters
Eu antitrust regulators close investigation into edwards lifesciences after company withdraws anti-copycat policy - marketscreener.com
Achy Breaky Heart: The FTC Blocks Edwards-JenaValve Aortic Device Deal - marketscreener.com
What’s the outlook for Edwards Lifesciences Corporation’s sectorQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update - Finviz
Envestnet Asset Management Inc. Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences completes key study on SAPIEN XT THV - MSN
Is Edwards Lifesciences Corporation stock a smart retirement pickPortfolio Value Summary & Free Accurate Trade Setup Notifications - mfd.ru
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day - The AI Journal
Rhumbline Advisers Acquires 15,792 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025 - Yahoo Finance
Halper Sadeh LLC Encourages Edwards Lifesciences - GlobeNewswire
Edwards Lifesciences Corporation $EW Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Wells Fargo Raises Price Target for Edwards Lifesciences (EW) | - GuruFocus
Edwards Lifesciences Leans Into Growth After Strong Quarter - TipRanks
Edwards Lifesciences (EW): Truist Securities Maintains Hold Rati - GuruFocus
Edwards Lifesciences (EW) Analyst Ratings Update: Price Target L - GuruFocus
Edwards Lifesciences (NYSE:EW) Advances Structural Heart Solutions - Kalkine Media
Edwards Lifesciences Corp (NYSE:EW) Issues Upbeat Guidance - FXDailyReport.Com
Rothschild & Co Redburn Adjusts Edwards Lifesciences PT to $94 From $93, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences 2026 Growth Targets Achievable, RBC Says - marketscreener.com
Piper Sandler Raises Price Target for Edwards Lifesciences (EW) to $100 | EW Stock News - GuruFocus
Edwards focuses on earlier TAVR adoption - MedTech Dive
Stifel reiterates Buy rating on Edwards Lifesciences stock at $110 target - Investing.com
Wells Fargo Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
Truist Securities Adjusts Price Target on Edwards Lifesciences to $89 From $92, Maintains Hold Rating - marketscreener.com
Wells Fargo & Company Raises Edwards Lifesciences (NYSE:EW) Price Target to $100.00 - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Q4 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $100 From $96, Maintains Overweight Rating - marketscreener.com
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $87 From $88, Maintains Market Perform Rating - marketscreener.com
Baird Adjusts Price Target on Edwards Lifesciences to $87 From $90, Maintains Neutral Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $95 From $108, Maintains Buy Rating - marketscreener.com
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.47%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):